4 news items
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
URGN
17 Jun 24
@tdsecurities.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, telephone: (212) 518-5548
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
URGN
17 Jun 24
Department, 330 Madison Avenue, New York, NY 10017, telephone: (212) 518-5548, email
Reported Sunday, JELMYTO Demonstrates Remarkable 86% Recurrence-Free Survival Rate At 24 Months For All Studied Patient And Disease Characteristics
URGN
6 May 24
response to the initial induction of this new treatment," said Adam Feldman, M.D., M.P.H., Urologic Oncologist in the Department of Urology
New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy
URGN
5 May 24
treatment," said Adam Feldman, M.D., M.P.H., Urologic Oncologist in the Department of Urology at Massachusetts General Hospital, and Director
- Prev
- 1
- Next